Armata Pharmaceuticals, Inc. (ARMP) has received acceptance from the U.S. Food and Drug Administration (FDA) on its initial pediatric study plan for AP-SA02 for the treatment of complicated Staphylococcus aureus bacteremia.

老虎证券2026/07/13 11:23

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

GE HealthCare (GEHC.US) plans to acquire Sofie for $1 billion, aiming for high growth in the radiopharmaceutical sector

GE Healthcare plans to acquire Sofie for about $1 billion, aiming to expand recurring revenue by combining imaging devices with radiodiagnostic agents, in response to weak stock performance and pressure from activist investors.

智通财经•2026/09/14 02:36

Silver Price Forecast: XAG/USD bears have the upper hand below $64.75-$64.85 confluence

FXStreet•2026/09/14 02:33

Japanese Yen edges lower vs USD amid Middle East jitters as Fed, BoJ meetings loom

FXStreet•2026/09/14 02:24

Cardone increases holdings by 20 BTC, Metaplanet sets up presence in Asia asset management center

AiCoin•2026/09/14 02:19